of the life claims declined, 0.85 per cent were due to mis-representation and 0.16 per cent due to the definition of terminal illness not being met.
.
.
another new drug in the migraine pipeline is lasmiditan. it works the same way as triptans. but unlike the triptans, it doesn't constrict
.
richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine.
.
.
.
.